Study: Hibbs 2024, JAMA Network Open
Cancer Trial Eligibility and Therapy Modifications for Individuals With Duffy Null-Associated Neutrophil Count
Citation
Hibbs SP, Aiken L, Vora K, Mowete C et al (2024). JAMA Network Open. PubMed id 39259539.
Cards that cite this study (1)
Each card gives its own wording for who was tested, how and what was found.
- A low white cell count that may be Duffy-null (neutrophil count) Tier B moderate
B Phase 3 cancer trials for prostate, breast, melanoma, colorectal and lung cancers, 2021-2023 (n=382)
Cross-sectional analysis of trial exclusion criteria and chemotherapy dose-modification rules.
Of 289 eligible trials, 221 (76.5%, 95% CI 71.1-81.2) excluded patients whose neutrophil counts were within the Duffy-null reference range. Colorectal trials had the highest exclusion proportion (86.4%), prostate the lowest (47.8%).
As recorded in this card: Hibbs SP, Aiken L, Vora K, Mowete C et al (2024), JAMA Network Open, [bibliometric]
This is information, not medical advice. If you are worried, see a doctor or pharmacist. How we grade the evidence. All studies.